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Abstract
Myeloproliferative syndromes are cell proliferation involving one or more 
medullary lines without blocking maturation. Chronic myeloid leukemia (CML) is 
the most common of these syndromes, it corresponds to the monoclonal prolifera-
tion of a multipotent stem cell; the myeloblastic or lymphoblastic transformation 
of CM. has a poor prognosis. The Philadelphia chromosome t(9;22)(q34;q11) is the 
first cytogenetic abnormality that has been associated with a malignant process. 
It is found in 89 to 95% of CML. The search for the Philadelphia chromosome 
(Ph1) has multiple interests: Diagnostic, prognostic and in therapeutic monitor-
ing. The search for the Philadelphia chromosome by molecular cytogenetics makes 
it possible to remedy the poverty of cell suspensions in metaphase to take up the 
inconclusive results of classic cytogenetics on nuclei in interphase and to detect 
residual disease during therapeutic monitoring. Through the literature review, we 
highlight the importance of the identification of the Philadelphia chromosome in 
Myeloproliferative Syndromes for the improvement of the quality healthcare of the 
affected patients.
Keywords: Philadelphia chromosome, myeloproliferative syndromes, karyotype, 
diagnostic and prognostic interest
1. Introduction
Leukemias are clonal and acquired diseases of the hematopoietic stem cell or a 
precursor already committed to lymphoid and /or myeloid lineages [1]. hyperplasia 
produced a tissue that results from cell proliferation as myeloid pathology. Chronic 
myeloid leukemia (CML) is a monoclonal pathology of the pluripotent stem cell 
characterized by neoplastic granulocytic overproduction. This myeloproliferative 
syndrome has two particular characteristics:
• Its evolutionary mode consists of a chronic chemosensitive phase, followed by 
an acceleration phase, then an acute (or blast) transformation, ineluctable and 
chemoresistant.
• A quasi-constant clonal cytogenetic marker which is the Philadelphia Ph1 
chromosome or derived from chromosome 22. This chromosome abnormality 
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is generated from the reciprocal translocation involving the q34 band of 
chromosome 9 and the q11 band of chromosome 22.
The recent development of therapeutics targeted at the activity or stability of an 
oncogenic protein has recently been illustrated by the therapeutic successes obtained 
in the treatment of chronic myeloid leukemia and acute promyelocytic leukemia [1]. 
Until now cytogenetics has been the reference for structural abnormalities, in particu-
lar translocations, tools for precise diagnosis in certain disputed cases and the detection 
of residual diseases or possible relapses. However molecular cytogenetics can detect 
chromosomal abnormalities of small sizes not visible on metaphasic chromosomes 
(semi-cryptic). It is of particular interest in the analysis of acquired abnormalities 
and is involved in monitoring the persistence of an abnormal clone in order to detect 
predicted recurrent translocations and may also help characterize genes in the evolu-
tionary process of carcinogenesis. The current recommendations are based on high-
quality evidence reported in peer-reviewed journals, supplemented by expert group 
consensus. These recommendations apply to healthcare professionals who treat CML 
patients and CML patients to better understand their conditions and treatments [2].
2. Interest of chromosome Philadelphia in chronic myeloid leukemia
• The usual form or standard translocation.
It is the translocation of a distal fragment of the long arm of chromosome 22 
(fragment 22q11.2) to the distal part of the long arm of chromosome 9 with recovery 
of a deleted part of the long arm of chromosome 9 on the long arm of chromosome 
22. It is therefore a reciprocal translocation, without loss of chromosomal material 
(Figure 1(a,b)).
Since this date, we defined the standard Philadelphia chromosome as: t(9;22) 
(q34;q11) or t(9; 22)(q34.1; q11.21).
3.  Diagnostic interest of chromosome Philadelphia in chronic myeloid 
leukemia
3.1 The chronic phase
The Philadelphia chromosome is the only element allowing a diagnosis in 
hyperleukocytosis. It is found in 89 to 95% of CML cells: In the granulomonocytic, 
Figure 1. 
(a) Result of a metaphase karyotype not classified in the R-band. (the circle indicates the Ph1 chromosome).  
(b) Partial RHG band karyotype of one of our patients: t(9;22)(q34;q11).
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erythroblastic and B lymphocytic lines [3]. In most cases, CML is diagnosed on 
clinical and hematologic data alone. The differential diagnosis arises with all the 
pathologies that are accompanied by hyperleukocytosis with mild myelemia.
• The Ph1 chromosome: Diagnoctic key
The almost constant presence of this translocation in CML offers clinicians an 
additional diagnostic tool especially in myeloproliferative syndromes (MPS), chro-
mosome 22 can be translocated to a chromosome other than chromosome 9 or else 
participates in a complex translocation of most interest, often three chromosomes 
of which the 22 and 9 one speaks then of Ph1 variant as opposed to the standard Ph1 
chromosome. This same tanslocation t(9;22)(q34;q11) is found in a non-negligible 
percentage in ALL and AML.
3.2 Differential diagnosis in the acute phase
In acute leukemia, there is an accumulation of immature precursors of the 
hematopoietic lineage involved in the Bonne marrow, blood, or other tissue patholo-
gies. The acutization phase CML disease there is a significant hyperleukocytosis 
with the presence of the Philadelphia chromosome on all mitoses. This acutization 
phase is preceded by the appearance of secondary anomalies: Trisomy 8, duplication 
of Ph1, and isochromosome 17, which conditions a poor prognosis.
We also find the Philadelphia chromosome:
• In 5% of acute lymphoblastic leukemia (ALL) in children and 20–30% of ALL 
in adults and also found in acute myeloid leukemia, In acute myeloid leukemia 
type 1 (LAM1) and LAL1 [4].
3.3 Other myeloproliferative syndromes
Essential thrombocythemia, myeloid splenomegaly, polycythemia vera or vaquez 
disease and chronic myelomonocyte leukemia (CMML) have the same phenotype as 
show in certain forms of CM. For this reason, it is important to confirm the diagno-
sis of chronic myelogenous leukemia by cytogenetic study or molecular biology [5]. 
Sometimes to give a right diagnosis is complicated so only the karyotype or molecu-
lar biology tests can help for that. The first test looks for the presence or not of the 
Ph1 while the other molecular biology tests investigate the BCR-ABL rearrangement.
3.4 Chronic myeloid leukemia in children
Chronic myeloid leukemia in children: There are two clinically and genetically 
distinct forms:
• The adult form occurring beyond the age of two years resembles in all respects 
a Ph1 + CML with the presence of the cytogenetic marker Ph1 + and break 
points in M-BCR especially in 5 ‘[6, 7].
• The juvenile form before the age of two characterized by a peculiar clinical 
picture and a normal karyotype in most cases otherwise the most frequent 
chromosomal aberration is monosomy 7.
In some cases, the Ph1 chromosome may be masked due to the size of the frag-
ment translocated which is submicroscopic, molecular cytogenetics are then used 
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(in situ hybridization: FISH) or real-time PCR search for the Philadelphia chromo-
some is necessary to confirm the diagnosis of CML and to monitor progress under 
certain anti-mitotic drugs (Figure 2).
In onco-hematology, FISH provides a decisive complement to the diagnosis, 
the prognosis and monitoring of targeted therapies. In leukemia chronic myeloid 
this technique highlights the fusion of genes BCR and ABL which characterize the 
Philadelphia chromosome (Ph). FISH is particularly interesting in the cytogenetic 
monitoring of CML. In due to culture problems (low mitotic index and the quality 
of the metaphases poor according to European Leukemia Net 2009. This service 
is currently offered to patients with CML as part of the cytogenetic monitoring of 
their disease (Figure 3).
3.5 Variant translocations
Variant translocations fall into two subgroups: Simple variants and complex 
variants; their definitions are based on the results of R, G banding and molecu-
lar biology. Although it is very common, it is quickly learned that the t(9;22) 
translocation is not pathognomonic for CML and it has several variants: the 
Ph1 (+) variants, the masked Ph1 chromosome and the Ph1 (−) variants. All 
chromosomes except Y are involved in the variant form of Ph1 especially chro-
mosomes 3, 11, 12, 14 and 17 [8]. The variants can all be considered as complex 
translocations since the molecular genetic investigations of the supposed simple 
variants show that they involve at least three chromosomes and always the 9 and 
the 22 [9].
Figure 3. 
FISH image of BCR/ABL positive rearranged metaphase.
Figure 2. 
The Philadelphia chromosome can be masked because of the size of the translocated fragment which is 
submicroscopic.
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3.6 The blast transformation
In this phase, 65 to 80% of patients develop additional chromosomal aberra-
tions not due to chance which precede clinical and hematological manifestations 
by several months and which can serve as indicators prognosis [10, 11]. Secondary 
anomalies appear: Double chromosome Philadelphia, trisomy 8, isochromosome 17 
and trisomy 19. These four additional abnormalities are part of the clonal course in 
70% of CML Other, more rarely encountered anomalies seem to be due to chance, 
thus taking the minor pathways. In more than 50% of cases, they are represented by:
• Monosomies: Y, 7, 17.
• Down’s syndrome: 17 and 21.
• And the translocation t(3;21)(q26;q22) which has the characteristic of being 
accompanied by medullary fibrosis [12].
A quarter of patients [10, 11] will not develop any additional abnormalities and 
will keep Philadelphia alone for the duration of their survival.
3.7 Chronic myeloid leukemia with secondary abnormalities
The following partial karyotypes show the association of certain additional 
abnormalities to the Philadelphia chromosome (Ph1) in our patients. However, the 
therapeutic and prognostic approach is totally different. It is therefore necessary:
Make a positive diagnosis for CML.
• Correct the diagnosis of certain contentious cases.
• Specify the evolutionary stage.
• And make a differential diagnosis with myeloprolifirative and myelodysplastic 
syndromes.
During the blast phase of CML at Ph1 (+), analysis determines as a factor of poor 
prognosis [10]. As for the Philadelphia chromosome alone, it appears to have an 
independent prognostic value [13].
4. Prognostic interest of chromosome Philadelphia in CML
Evaluating the prognosis of CML using clinical-biological criteria can predict 
the probable date of onset of blast transformation which amounts to determining 
the probable duration of the chronic phase. As regards the cytogenetic criterion, 
it must be defined and homogeneous. The prognoses of Ph1 (+) CML and Ph1 (−) 
CML should be studied separately because we have seen the current difficulties of 
including the Ph1 (−) form in the nosological framework of CML.
In our medical genetics’ laboratory. The suspected diagnosis was CML in 69 
patients, unlabeled SMP in the remaining 22 patients (Table 1).
• Culture failure in 6 cases.
• Normal karyotype in 25 cases.
• Philadelphia chromosome or t(9;22)(q34;q11) in 60 cases.
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The cytogenetic criterion is requested at two levels:
• For the initial assessment of prognosis at the time of diagnosis of CML in 
combination with baseline clinical and hematologic data.
• Then to assess the prognosis later during the blast transformation.
During the chronic phase of Ph1 (+) CML and without the knowledge of multi-
parametric analyzes, it has been shown that the most significant prognostic factors 
which determine the duration of survival are [14]:
• The presence of additional clonal chromosomal abnormalities (relative risk 
“RR” = 4.5).
• Circulating blasts greater than 5% “RR = 1.8”.
• A hemoglobin rate of less than 10 g / dl “RR = 1.30”.
Figure 4. 
(a) Presence of an extra Ph1 chromosome and trisomy 21. (b) Partial trisomy 8. (c) Partial band karyotype 
RHG: T(9;X;22).
Table 1. 
(a) Cytogenetic analysis in myeloproliferative syndromes 91 patients. (b) Frequency of the Philadelphia 
chromosome (Ph1).
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• Thrombocytopenia.
• Leukocytosis>20.109 / l.
• Non-lymphoid blast cells.
• A clonal evolution a \ double chromosome Ph1, a trisomy 8, and typical aberra-
tions of the acute phase (Ph1 (+), i(17q), hypodiploidy or hyperdiploidy).
• Lack of response to treatment.
It is interesting to note that the double chromosome Ph1 or trisomy 8 are more 
frequent in acute transformations of the AML, ALL type and that they respond 
poorly to treatment (Figure 4).
5. Surveillance of residual disease
Residual disease is defined as the number of malignant cells persisting after 
cytotoxic treatment, the eradicative action of which is intended to be as complete as 
possible: Chemotherapy, ionizing radiation, bone grafting. The residual malignant 
cells which escape this treatment can be the cause of a relapse hence the need to 
quantify them as precisely as possible. Before the introduction of molecular biology, 
hematologists had at their disposal various means of approach to define the biological 
remission of a hemopathy: Cytology, cytogenetics, immunology. In the best case, the 
sensitivity of these techniques did not make it possible to detect less than one residual 
cell in 100, a very insufficient sensitivity threshold to help clinician to decide for 
adequate treatment and to evaluate the quality control of the graft. The treatments 
envisaged must be carried out in order to obtain hematological remission and if pos-
sible a complete eradication of the Ph1 (+) cells (cytogenetic remission) with regard 
to chronic myeloid leukemia, the evolution takes place in two stages: A first chronic or 
myelocytic phase easily controlled by usual therapies then a second inconstant transi-
tion phase called acceleration with resistance to conventional chemotherapy, follow-
ing which an acute transformation occurs, often of the terminal acute myelogenous 
leukemia type, constantly fatal, inevitable on average 3 to 4 years after diagnosis.
6. Contribution of oncocytogenetics in chronic myeloid leukemia
The molecular consequence is the formation of a BCR-ABL fusion gene, tran-
scribed into 8.5 Kb mRNA and translated into 210 Kd protein with greater tyrosine 
kinase activity compared to the normal protein of the proto oncogene c-ABL 
from 145 Kb, this protein is involved in the pathological process of CML [15]. The 
molecular biology techniques applied to DNA, mRNA (RT-PCR) and encoded 
Chromosomes RNAm Protein
9 ARNm c-abl P145c−abl
22 ARNm bcr P160bcr
22q- ARNm bcr-abl P210bcr−abl
Table 2. 
The chromosomes involved and their molecular consequences.
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proteins have made it possible to specify the nature of the molecular events result-
ing from the rearrangement of BCR-ABL (Table 2).
Fluorescent in situ hybridization (FISH) using specific probes provides a 
useful tool for the detection of t(9;22)(q34;q11) and BCR-ABL rearrangement [16] 
(Figure 3). The fusion protein has a strong activity tyrosine kinase responsible for 
tumor development (Figure 5).
7. Conclusion
In summary, Philadelphia chromosome is an abnormal chromosome 22, result-
ing from a reciprocal translocation between chromosomes 9 and 22, a specific 
marker in chronic myeloid leukemia. His research in myeloproliferative syndromes 
has multiple interests: Diagnostic, prognostic and therapeutic follow-up which 
contributes to better patient care. Its demonstration in myeloproliferative syn-
dromes makes it possible to confirm the nature of the disease and to distinguish 
between CM and other myeloproliferative syndromes.
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Figure 5. 
Schema the Philadelphia chromosome t(9;22)(q34;q11) results in the fusion of BCR genes on chromosome 22 
and ABL on chromosome 22. The fusion protein has a strong activity tyrosine kinase responsible for tumor 
development.
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